Gilead is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay, specifically for the liver disease med seladelpar.

As Gilead Sciences awaits the progression of California state litigation over its alleged delay of safer HIV drugs, the company is biding its time with a proposed $40 million settlement to quell ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that they paid kickbacks to boost sales. | Authorities say Gilead paid ...

A Washington, D.C. federal court said in a decision made public Wednesday that the U.S. government broke agreements with Gilead Sciences Inc when the Centers for Disease Control and Prevention ...